11. Behandling av inoperabel lokalavansert eller metastasert sykdom

Agarwala, S. S. (2009). Current systemic therapy for metastatic melanoma. Expert review of anticancer therapy, 9(5), 587-95.

Agarwala, S. S., Kirkwood, J. M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., Atkins, M., Buzaid, A., ... Rankin, E. M. (2004). Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. Journal of clinical oncology, 22(11), 2101-7.

Ascierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., ... Weber, J. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology, 21(11), 1465-1477.

Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., ... Larkin, J. (2016). Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. The Lancet. Oncology, 17(9), 1248-60.

Atkins, M. B., Lee, S. J., Chmielowski, B., Ribas, A., Tarhini, A. A., Truong, T., Davar, D., O'Rourke, M. A., ... Kirkwood, J. M. (2021). DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134. Journal of clinical oncology, 39(36_suppl), 356154.

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., ... National Comprehensive Cancer Network (2018). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology, 36(17), 1714-1768.

Brennum, J., Kosteljanetz, M., & Roed, H. M. (2002). Hjernemetastaser. Ugeskrift for læger, 164(27), 3522-3526.

Czarnecka, A. M., Teterycz, P., Mariuk-Jarema, A., Lugowska, I., Rogala, P., Dudzisz-Sledz, M., Switaj, T., & Rutkowski, P. (2019). Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. Targeted oncology, 14(6), 729-742.

Davies, M. A., Saiag, P., Robert, C., Grob, J. J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., ... Long, G. V. (2017). Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. The Lancet. Oncology, 18(7), 863-873.

Digernes, I., Grøvik, E., Nilsen, L. B., Saxhaug, C., Geier, O., Reitan, E., Sætre, D. O., Breivik, B., ... Emblem, K. E. (2018). Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery. Advances in radiation oncology, 3(4), 559-567.

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., ... Flaherty, K. T. (2018). Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 19(10), 1315-1327.

Eggermont, A. M., & Kirkwood, J. M. (2004). Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. European journal of cancer, 40(12), 1825-1836.

Fenig, E., Eidelevich, E., Njuguna, E., Katz, A., Gutman, H., Sulkes, A., & Schechter, J. (1999). Role of radiation therapy in the management of cutaneous malignant melanoma. American journal of clinical oncology, 22(2), 184-6.

Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., ... Kluger, H. M. (2016). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet. Oncology, 17(7), 976-983.

Gondi, V., Pugh, S. L., Tome, W. A., Caine, C., Corn, B., Kanner, A., Rowley, H., Kundapur, V., ... Mehta, M. P. (2014). Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. Journal of clinical oncology, 32(34), 3810-6.

Grünhagen, D. J., van Etten, B., Brunstein, F., Graveland, W. J., van Geel, A. N., de Wilt, J. H., & Eggermont, A. M. (2005). Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Annals of surgical oncology, 12(8), 609-15.

Helsedirektoratet (2019). Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen (rev. utg.) Oslo: Hentet fra https://www.helsedirektoratet.no/retningslinjer/palliasjon-i-kreftomsorgen-handlingsprogram

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., ... Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine, 363(8), 711-23.

Hong, A. M., Fogarty, G. B., Dolven-Jacobsen, K., Burmeister, B. H., Lo, S. N., Haydu, L. E., Vardy, J. L., Nowak, A. K., ... Thompson, J. F. (2019). Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of clinical oncology, 37(33), 3132-3141.

Hong, A. M., Suo, C., Valenzuela, M., Haydu, L. E., Jacobsen, K. D., Reisse, C. H., & Fogarty, G. (2014). Low incidence of melanoma brain metastasis in the hippocampus. Radiotherapy and oncology, 111(1), 59-62.

Hunter, G. K., Suh, J. H., Reuther, A. M., Vogelbaum, M. A., Barnett, G. H., Angelov, L., Weil, R. J., Neyman, G., & Chao, S. T. (2012). Treatment of five or more brain metastases with stereotactic radiosurgery. International journal of radiation oncology, biology, physics, 83(5), 1394-8.

Jimenez-Requena, F., Delgado-Bolton, R. C., Fernandez-Perez, C., Gambhir, S. S., Schwimmer, J., Perez-Vazquez, J. M., & Carreras-Delgado, J. L. (2010). Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. European journal of nuclear medicine and molecular imaging, 37(2), 284-300.

Kroon, H. M., & Thompson, J. F. (2009). Isolated limb infusion: a review. Journal of surgical oncology, 100(2), 169-77.

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., ... Wolchok, J. D. (2019). Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine, 381(16), 1535-1546.

Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J., ... McArthur, G. A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. The Lancet. Oncology, 19(5), 672-681.

Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., ... Schadendorf, D. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet. Oncology, 13(11), 1087-95.

Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., ... Hodi, F. S. (2012). Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet. Oncology, 13(5), 459-65.

Menzies, A. M., Haydu, L. E., Visintin, L., Carlino, M. S., Howle, J. R., Thompson, J. F., Kefford, R. F., Scolyer, R. A., & Long, G. V. (2012). Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clinical cancer research, 18(12), 3242-9.

Meyer, T., Merkel, S., Goehl, J., & Hohenberger, W. (2000). Surgical therapy for distant metastases of malignant melanoma. Cancer, 89(9), 1983-91.

Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., ... Thatcher, N. (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of clinical oncology, 18(1), 158-66.

Miller, J. D. (1993). Surgical excision for single cerebral metastasis?. Lancet, 341(8860), 1566.

Noël, G., Simon, J. M., Valery, C. A., Cornu, P., Boisserie, G., Ledu, D., Hasboun, D., Tep, B., ... Mazeron, J. J. (2002). Linac radiosurgery for brain metastasis of melanoma. Stereotactic and functional neurosurgery, 79(3-4), 245-55.

Olson, D. J., Eroglu, Z., Brockstein, B., Poklepovic, A. S., Bajaj, M., Babu, S., Hallmeyer, S., Velasco, M., ... Luke, J. J. (2021). Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of clinical oncology, 39(24), 2647-2655.

Overett, T. K., & Shiu, M. H. (1985). Surgical treatment of distant metastatic melanoma. Indications and results. Cancer, 56(5), 1222-30.

Park, S. S., Dong, H., Liu, X., Harrington, S. M., Krco, C. J., Grams, M. P., Mansfield, A. S., Furutani, K. M., ... Kwon, E. D. (2015). PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer immunology research, 3(6), 610-9.

Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. (1990). A randomized trial of surgery in the treatment of single metastases to the brain. The New England journal of medicine, 322(8), 494-500.

Patel, B. G., Ahmed, K. A., Johnstone, P. A., Yu, H. H., & Etame, A. B. (2016). Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma research, 26(4), 382-6.

Pires da Silva, I., Ahmed, T., Reijers, I. L. M., Weppler, A. M., Betof Warner, A., Patrinely, J. R., Serra-Bellver, P., Allayous, C., ... Long, G. V. (2021). Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. The Lancet. Oncology, 22(6), 836-847.

Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., ... Long, G. V. (2019). Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England journal of medicine, 381(7), 626-636.

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Rutkowski, P., Hassel, J. C., ... Atkinson, V. (2020). Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. Journal of clinical oncology, 38(33), 3937-3946.

Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., ... Long, G. V. (2019). Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet. Oncology, 20(9), 1239-1251.

Sampson, J. H., Carter, J. H. ,. J., Friedman, A. H., & Seigler, H. F. (1998). Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. Journal of neurosurgery, 88(1), 11-20.

Sloan, A. E., Nock, C. J., & Einstein, D. B. (2009). Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer control : journal of the Moffitt Cancer Center, 16(3), 248-55.

Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., ... Weller, M. (2017). Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-oncology, 19(2), 162-174.

Sperduto, P. W., Chao, S. T., Sneed, P. K., Luo, X., Suh, J., Roberge, D., Bhatt, A., Jensen, A. W., ... Mehta, M. (2010). Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. International journal of radiation oncology, biology, physics, 77(3), 655-61.

Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., ... Margolin, K. (2018). Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. The New England journal of medicine, 379(8), 722-730.

Waldeland, E., Brustugun, O. T., Ramberg, C., & Helland, Å. (2012). Stereotaktisk bestråling av columnametastaser. Tidsskrift for den Norske legeforening, 132(22), 2478-2479.

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., ... Hodi, F. S. (2022). Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology, 40(2), 127-137.

Xing, Y., Bronstein, Y., Ross, M. I., Askew, R. L., Lee, J. E., Gershenwald, J. E., Royal, R., & Cormier, J. N. (2011). Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. Journal of the National Cancer Institute, 103(2), 129-42.

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., Yamanaka, K., Sato, Y., ... Tsuchiya, K. (2014). Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet. Oncology, 15(4), 387-95.